Report of the ISHLT Working Group on Primary Lung Graft Dysfunction part IV: recipient-related risk factors and markers.
about
Anti-type V collagen humoral immunity in lung transplant primary graft dysfunctionPrimary Graft Dysfunction after Lung TransplantationLung transplantation in IIP: A reviewPrimary graft dysfunction: lessons learned about the first 72 h after lung transplantationLung transplantation for cystic fibrosisSoluble p-selectin and the risk of primary graft dysfunction after lung transplantation.Plasma cytokines and chemokines in primary graft dysfunction post-lung transplantation.Construct validity of the definition of primary graft dysfunction after lung transplantation.Recipient-related clinical risk factors for primary graft dysfunction after lung transplantation: a systematic review and meta-analysis.Association of protein C and type 1 plasminogen activator inhibitor with primary graft dysfunction.The relationship between plasma lipid peroxidation products and primary graft dysfunction after lung transplantation is modified by donor smoking and reperfusion hyperoxia.Diastolic Dysfunction Increases the Risk of Primary Graft Dysfunction after Lung TransplantClinical risk factors for primary graft dysfunction after lung transplantationPrimary graft dysfunction.Biomarkers of lung injury in primary graft dysfunction following lung transplantation.Physician assistant model for lung procurements: a paradigm worth consideringMassive donor transfusion potentially increases recipient mortality after lung transplantation.Protein biomarkers associated with primary graft dysfunction following lung transplantation.Quantitative Evidence for Revising the Definition of Primary Graft Dysfunction After Lung Transplant.Clinical Risk Factors and Prognostic Model for Primary Graft Dysfunction after Lung Transplantation in Patients with Pulmonary Hypertension.Extracorporeal life support in lung and heart-lung transplantation for pulmonary hypertension in adults.Allogeneic blood transfusion in bilateral lung transplantation: impact on early function and mortality.A randomized, placebo-controlled trial of aprotinin to reduce primary graft dysfunction following lung transplantation.Onset of Inflammation With Ischemia: Implications for Donor Lung Preservation and Transplant Survival.Pathophysiology and classification of primary graft dysfunction after lung transplantation.Marker Games: Seeking Better Biomarkers?Single lung transplantation with cardiopulmonary bypass.Expression profiling of human donor lungs to understand primary graft dysfunction after lung transplantation.Plasma intercellular adhesion molecule-1 and von Willebrand factor in primary graft dysfunction after lung transplantation.Recipient vascular endothelial growth factor serum levels predict primary lung graft dysfunction.
P2860
Q24630502-1DF941A5-D02B-48BF-ACD5-8780C9B7F1F8Q26745629-A1CF8582-8227-493C-9BCB-56237D5AD99DQ26774870-3AA617B9-14E6-4EEB-9EFD-5B4CCDB93ED7Q28084783-25AB2F67-42CE-4B1B-A4BE-E678A9887DF3Q28749501-D6D620BD-11B5-4146-90EA-7E564A4DB107Q33650349-BBAE1D6D-2DC2-4878-8D82-62E86CB728F0Q33653089-2E50DD85-7B5D-4D6E-AC8A-EAE6789D3DFFQ34238666-8F6D2D47-0317-4497-8BE0-9410D131D77FQ35127935-6FF01F3E-A6CF-466D-A632-11F8ED1FA543Q35855114-EFFF8DA3-D671-44B0-8DFC-0BA9FD6FEC44Q36768114-4B51EFA9-61B4-4EE2-9C5F-A3556E26F473Q37013126-AB389721-E671-4A31-9DAC-FE570CD0F8B2Q37070008-DE9A02FC-C6AE-4535-8CF6-34198FF4EC3BQ37670609-5CC13713-ED43-40BF-AF82-639DEECD76B8Q37755105-6CEE74B7-F412-4EC5-B28C-05C7C4AFAF99Q38148817-793025E8-9DFE-4A74-B40C-357DBCF40AB5Q39028611-74ECAD5D-5579-4DA5-8BC9-F30DBBE9CF94Q39107058-6794A411-37F2-4EC6-BD34-849B612571C5Q40057755-AD982B3E-1C8D-4482-838E-56814E59D18DQ40118127-0E6F8FEB-57A2-4ACD-B59A-2CBA9C9E9118Q40614559-0920FE6B-97EB-4719-AE27-E7047F4708AAQ41012109-9D0E1E4C-C50C-449F-B406-288B028071B6Q46003287-995A456B-AFA4-4460-8618-68D2D33BE59CQ46576466-992D8ACA-E940-45AB-9425-E1960D36FB3FQ47120100-67EFA2E7-FCD5-4CA1-B238-6716CFC82A24Q48178212-FDF8780F-CA4D-4FB0-BD82-419E2C30AE4FQ48300314-A526449A-135F-45A4-932F-4DBA40BF1469Q50915479-DC9D1BD5-26E4-4B5F-B2E4-58D76A96958BQ51904878-6B1C89AF-7790-4754-9840-DDB06F3E21C9Q53242921-8E4BFE7D-266D-4B43-9C48-20A25132EA50
P2860
Report of the ISHLT Working Group on Primary Lung Graft Dysfunction part IV: recipient-related risk factors and markers.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Report of the ISHLT Working Gr ...... ated risk factors and markers.
@ast
Report of the ISHLT Working Gr ...... ated risk factors and markers.
@en
type
label
Report of the ISHLT Working Gr ...... ated risk factors and markers.
@ast
Report of the ISHLT Working Gr ...... ated risk factors and markers.
@en
prefLabel
Report of the ISHLT Working Gr ...... ated risk factors and markers.
@ast
Report of the ISHLT Working Gr ...... ated risk factors and markers.
@en
P2093
P1476
Report of the ISHLT Working Gr ...... ated risk factors and markers.
@en
P2093
David M Follette
Heidi Böttcher
ISHLT Working Group on Primary Lung Graft Dysfunction
Joshua Sonett
Mark L Barr
Paul A Corris
Reda Girgis
Steven M Kawut
Timothy P Whelan
Wickii Vigneswaran
P304
P356
10.1016/J.HEALUN.2005.02.019
P577
2005-07-27T00:00:00Z